Author contributions Daphne Bot: acquisition of data, analysis and interpretation of data, and drafting of the manuscript
The phase 2 dose-ranging trial (NCT02970942) included 320 individuals with histologically proven MASH and hepatic fibrosis F1-F3, randomizing them 3:3:3:1:1:1 to daily subcutaneous administration of semaglutide 0.1, 0.2, or 0.4 mg, or placebo for 72 weeks [18]
MYB The ranscriptional activator Myb (MYB) is a cellular progenitor of the v-Myb oncogene and encode an oncogenic transcription factor that regulates various cellular functions by controlling the expression of a wide array of genes [135]
Jump to: Why you should trust us At Innerbody Research, we extensively test each health service we review whenever possible, including Henry Meds
It is not intended for : Human consumption Veterinary applications Medical treatment Diagnostic use Cosmetic use Therapeutic administration Researchers should follow all applicable institutional guidelines and laboratory safety procedures when handling experimental compounds